Background In recent years, neoadjuvant immunotherapy combined with chemotherapy has
been used to treat locally advanced non-small cell lung cancer (NSCLC); however, no data …

Background The recent novel conception of neoadjuvant immunotherapy has generated
interest among surgeons worldwide, especially the lack of experience involving surgical …

Background Previously reported results have shown promising efficacy of neoadjuvant
immunotherapy for resectable non–small cell lung cancer (NSCLC). However, no …

Background Resectable non-small cell lung cancer (NSCLC) patients have a high risk of
recurrence. Multiple randomized controlled trials (RCTs) have shown that neoadjuvant …

Objectives The combination of immunotherapy and chemotherapy has shown great efficacy
in stage IV non–small cell lung cancer (NSCLC) and is now widely used in clinical treatment …

Background Preoperative immunotherapy has shed light on the management of resectable
non-small cell lung cancer (NSCLC). However, whether neoadjuvant immunotherapy …

Background There are many studies on neoadjuvant immunotherapy for locally advanced
non‐small cell lung cancer (NSCLC) patients. Expert consensus recommends neoadjuvant …

Objectives Recent clinical studies have demonstrated that immunotherapy-based
neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell …

Background Lung cancer is currently the world's leading malignancy in terms of morbidity
and mortality. Neoadjuvant therapy is widely used in clinic to improve R0 resection rates and …

Background This open, observational clinical study aimed to investigate the efficacy, safety
and survival outcomes of neoadjuvant chemotherapy, neoadjuvant immunotherapy with …